Phosphoinositide 3-kinase inhibitor
drug class
Phosphoinositide 3-kinase inhibitors (PI3K inhibitors) are a class of medical drugs that are mainly used to treat advanced cancers. They function by inhibiting one or more of the phosphoinositide 3-kinase (PI3K) enzymes, which are part of the PI3K/AKT/mTOR pathway. This signal pathway regulates cellular functions such as growth and survival. It is strictly regulated in healthy cells, but is always active in many cancer cells, allowing the cancer cells to better survive and multiply. PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. They are examples of a targeted therapy. While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable.
After PI3K inhibitors had been under investigation as anti-cancer drugs for several years, the first one to be approved for treatment in clinical practice was idelalisib in 2014. Several others followed, and even more are still under development (see below).
There are different classes and isoforms of PI3Ks.
The public source identifies “Phosphoinositide 3-kinase inhibitor” as drug class. This brief keeps that definition visible, then builds a research path around Phosphoinositide, 3-kinase and inhibitor.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Phosphoinositide 3-kinase inhibitor”, the useful work is to connect “drug class” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 16, 2026. The linked authority identifier is Q7187512. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2014.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Phosphoinositide 3-kinase inhibitor”, its source revision and the description used here.
- Expand the search: follow Phosphoinositide 3-kinase inhibitor primary sources, Phosphoinositide 3-kinase inhibitor archive and Phosphoinositide research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Phosphoinositide 3-kinase inhibitor”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Phosphoinositide 3-kinase inhibitor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.